XXXX in organic @entity6426 : a preliminary report.

@entity1545 @entity1 @entity836 @entity308 @entity6426 @entity7298 @entity75 @entity542 @entity6126 @entity1091
Multiple lines of experimental evidence point to the involvement of endogenous opiates in appetite regulation. Post @entity1545 @entity1 often exhibit driven eating behaviour. Since this problem fails to respond to behaviour modification, appetite suppressants, @entity1091 , or any other usual approach, the use of the oral narcotic antagonist, @entity836 , was given to three such @entity1 . @entity836 binds multiple opiate receptor sites in the hypothalamus, including the kappa receptors which have been implicated in appetite regulation, the use of this narcotic antagonist in hypothalamic @entity7298 appears to be a rational approach to this intractable problem. In this open trial, lasting from 4 1/2 to 9 months, the minimal effective dose appeared to be in the range of 100 mg per day. No side-effects (for example elevations in liver enzymes) were noted. All of the @entity1 had an improved sense of well-being and their behaviours were less difficult to manage when on the @entity836 . The significance of this preliminary trial is that narcotic antagonists may have a role in the treatment of @entity75 @entity1 with @entity6426 . Also, @entity836 may be useful in treating other maladaptive behavioural consequences of @entity542 such as stealing, manipulation, demandingness, and @entity308 . Likewise, the effects on the deranged endocrine system, such as the @entity6126 , are significant and deserve further exploration.
